Skip to main content

Reply to comment

Ewing’s sarcoma

Posted in

Ewing’s sarcoma, first diagnosed 18.3.1996, histologically verified;  tumour resistant to both chemotherapy and radiotherapy. UKRAIN therapy started on 13 October 1997.

Ewing’s sarcoma

The patient, a 10 year-old girl, was treated in the high-risk arm of the EICESS 92 study. MRI examination of the pelvic region on 1.9.1997 showed progression in the cystic-edematous process. She was then treated  with combined Ukrain and local hyperthermia therapy. The therapy series consisted of 15 mg Ukrain in an infusion with 250 ml glucose and 5 g vitamin C, followed by local hyperthermia treatment. Treatment was administered every second day up to a total of 10 therapy sessions. MRI examination on 8.1.1998 showed no progression of the tumour. Subsequent therapy cycles caused regression of the tumour (see MRI on 15.6.1999 and 1.2.2000). MRI on 1.2.2001: Cystic residual defect in right femur, as  observed in previous examinations. No sign of a relapse or of metastases.

Ewing’s sarcoma, first diagnosed 22.11.1983, histologically verified, tumour resistant both to chemotherapy and radiotherapy. UKRAIN therapy started on 21 January 1984.

Ewing’s sarcoma

A 9 year-old girl had felt marked pain below the right knee joint in November 1983 following a slight injury. X-ray revealed Ewing’s sarcoma in the proximal portion of the right fibula. Hospital treatment included chemotherapy and cobalt therapy. X-rays confirmed that the patient’s tumour had not responded to radiation or chemotherapy and the tumour mass increased rapidly. One month after the end of chemotherapy, UKRAIN treatment was started at a dose of 5 mg i.m. for a total of 10 injections, combined with regional deep hyperthermia. The first series of UKRAIN therapy included three identical courses with a two-week pause between them. Six series of UKRAIN treatment were administered over the course of one year. Repeated x-rays showed reduction of the tumour mass.

Reply

CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.